|
Media Releases |
Financial Reports |
Presen-tations |
|
09/20/2007
|
|
|
|
| Basel, 20.09.2007 – Lonza announces the availability of BioWhittaker(r) brand ProNS0(TM) Chemically Defined (CD) Serum-free Media. ProNS0(TM) Media support maximal production of recombinant protein in NS0 cells. The NS0 cell line is widely used for recombinant mammalian protein expression in research and biotherapeutic applications. |
BioWhittaker(r) ProNS0(TM) CD Media consist of two optimized formulas to cover the broadest range of NS0 nutritional needs. Further maximization of protein production is possible by titration with companion ProNS0(TM) Lipid CD Supplement.
“These protein-free and non-animal origin products simplify product purification, enhance lot-to-lot consistency, and reduce regulatory burdens,” states Shawn Cavanagh, Head of Lonza Bioscience.
BioWhittaker(r) ProNS0(TM) 1 CD and ProNS0(TM) 2 CD Media, together with ProNS0(TM) Lipid CD Supplement, are designed to meet a growing demand for optimized NS0 formulations. This trio of NS0 products provides the answer to maximal protein productivity.
For more information on this product or to place an order, please visit www.lonzabioscience.com/prod.ProNSO. For technical service please call +1 800-521-0390.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor / Media Relations Lonza
Janet White
Tel +41 61 316 8566
Fax +41 61 316 9566
janet.white@lonza.com
Media Relations Lonza
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
 Protein Expression Media){kind=small}